Internal Medicine

UPMC

Questions discussed in this category

How do you manage endocrine therapy for premenopausal women with breast cancer who are heterozygous for factor V Leiden but have no history of thrombosis?

1 Answer available

Papers discussed in this category

Journal of the National Cancer Institute, 2010-07-07

Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer.

J Natl Cancer Inst, 2006 Jul 5

Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial.

J. Natl. Cancer Inst., 2010-07-07

Tamoxifen and the factor V Leiden mutation.

J. Clin. Oncol., 2003-10-01

Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer.

Related Topics in Internal Medicine